Targeted Antigens of CAR-T Cell Therapy Information
Target General Information | Top | ||||
---|---|---|---|---|---|
Target ID | T10877 | Target Info | |||
Target Name | Cyclic ADP-ribose hydrolase 1 (CD38) | ||||
Synonyms | cADPr hydrolase 1; T10; Cyclic ADPribose hydrolase 1; ADPribosyl cyclase 1; ADPRC 1; ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1; ADP-ribosyl cyclase 1; 2'-phospho-cyclic-ADP-ribose transferase; 2'-phospho-ADP-ribosyl cyclase/2'-phospho-cyclic-ADP-ribose transferase; 2'-phospho-ADP-ribosyl cyclase | ||||
Target Type | Successful Target | ||||
Gene Name | CD38 | ||||
Biochemical Class | Glycosylase | ||||
UniProt ID |
Targeted Antigens of CAR-T Cell Therapy | Top | ||||
---|---|---|---|---|---|
CAR T-Cell Therapy Drug(s) | Anti-CD38 CAR-T cells | Drug Info | Phase 1/2 | Multiple myeloma | [1] |
CD38 CAR T cells | Drug Info | Phase 1/2 | Multiple myeloma | [2] | |
CD38 CAR-T Cell | Drug Info | Phase 1/2 | Acute lymphoblastic leukaemia | [3] | |
CD38-specific gene-engineered T cells | Drug Info | Phase 1/2 | Acute myeloid leukaemia | [4] | |
Anti-CD38 CAR-T cells | Drug Info | Phase 1 | Multiple myeloma | [5] | |
CART-38 cells | Drug Info | Phase 1 | Myelodysplastic syndrome | [6] | |
CD38 CAR-T | Drug Info | Phase 1 | Multiple myeloma | [7] | |
CAR-T cells targeting CD38 | Drug Info | Clinical trial | Multiple myeloma | [8] | |
CAR-T cells targeting CD38 | Drug Info | Preclinical | Acute myeloid leukaemia | [9] |
References | Top | ||||
---|---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | ||||
REF 2 | ClinicalTrials.gov (NCT03271632) Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma | ||||
REF 3 | ClinicalTrials.gov (NCT03754764) A Feasibility and Safety Study of CD38 CAR-T Cell Immunotherapy for Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T Adoptive Cellular Immunotherapy | ||||
REF 4 | ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia | ||||
REF 5 | ClinicalTrials.gov (NCT03464916) Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients | ||||
REF 6 | ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS | ||||
REF 7 | Clinical pipeline report, company report or official report of Sorrento Therapeutics. | ||||
REF 8 | ClinicalTrials.gov (NCT03473496) CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma | ||||
REF 9 | ClinicalTrials.gov (NCT03473457) CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.